Abstract:
BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis. METHODS:Targeted next-generation sequencing (NGS) mutation profiling was performed on samples from 42 NSCLC patients confirmed positive for ALK rearrangements by fluorescence in situ hybridization or immunohistochemistry who experienced disease progression after crizotinib treatment. RESULTS:ALK rearrangements were not confirmed in six patients (14%) with other potential oncogenic drivers identified by NGS, who therefore did not respond to crizotinib and had significantly shorter overall survival (OS) compared to NGS ALK -positive patients. Fifteen ALK activating mutations were detected in 8 out of 26 post-treatment samples (31%), among which ALK L1196M and G1269A were the most common acquired mutations detected in half of the patients with ALK activating mutations. Dynamic monitoring of the genetic evolution in one patient revealed both spatial and temporal heterogeneity of resistant mechanisms during different ALK-TKI treatment courses. Activation of ALK downstream or bypass pathways was detected in patients without ALK activating mutations, such as genetic alterations in PIK3CA, MET, and KRAS. Interestingly, we identified two patients with acquired mutations in the DNA mismatch repair gene POLE, which resulted in a dramatically increased tumor mutation burden, and might contribute to the poor response to crizotinib. CONCLUSIONS:Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJdoi
10.1111/1759-7714.12791subject
Has Abstractpub_date
2018-09-01 00:00:00pages
1093-1103issue
9eissn
1759-7706issn
1759-7714journal_volume
9pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:This study aims to evaluate the incidence and characteristics of chyle leakage after curative oncologic esophagectomy, and the effectiveness of thoracic duct ligation. METHODS:This is a retrospective cohort study using the medical records of 1514 patients who underwent curative esophagectomy for esophageal ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12105
更新日期:2014-09-01 00:00:00
abstract:BACKGROUND:As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information o...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12127
更新日期:2014-11-01 00:00:00
abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12275
更新日期:2016-01-01 00:00:00
abstract::Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13588
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13644
更新日期:2020-12-01 00:00:00
abstract::Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2012.00167.x
更新日期:2013-08-01 00:00:00
abstract:BACKGROUND:A giant thoracic neoplasm is extremely rare and poorly understood. Our systemic study introduced computed tomography angiography (CTA) with three-dimensional (3D) reconstruction imaging and evaluated correlations between imaging, pathology, and surgical management. METHODS:Data from 45 patients undergoing s...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12448
更新日期:2017-09-01 00:00:00
abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13163
更新日期:2019-10-01 00:00:00
abstract::Esophageal cancer with a history of distal gastrectomy is a clinical problem. To our knowledge there have been no reports of remnant stomach fed from the left gastroepiploic artery being used in esophageal reconstruction. We, herein, report four cases of esophagogastric reconstruction using remnant stomach with a sing...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12054
更新日期:2014-03-01 00:00:00
abstract::A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12244
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12925
更新日期:2019-02-01 00:00:00
abstract::Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13589
更新日期:2020-10-01 00:00:00
abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12362
更新日期:2016-09-01 00:00:00
abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12277
更新日期:2015-11-01 00:00:00
abstract:BACKGROUND:Esophageal cancer is among the leading cancer types in Inner Mongolia. This study aimed to investigate the incidence and mortality rates of esophageal cancer in 2015 and the trends in these rates in the 2010-2015 period in this region. METHODS:National Colorectal Cancer Roundtable (NCCR) screening methods a...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13552
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12336
更新日期:2016-04-26 00:00:00
abstract:BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13641
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13336
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND: The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00152.x
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12967
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12242
更新日期:2015-07-01 00:00:00
abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12617
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13212
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:This study investigates the outcome of synchronous stage IV non-small cell lung cancer (NSCLC) patients who received radical thoracic radiotherapy (TRT). METHODS:We retrospectively reviewed the charts of stage IV NSCLC patients treated with TRT between January 2007 and December 2011. Radiotherapy was consid...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12305
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12426
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13226
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13195
更新日期:2019-11-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13162
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13364
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13366
更新日期:2020-04-01 00:00:00